Literature DB >> 11275256

Cholinesterase-like catalytic antibodies: reaction with substrates and inhibitors.

G Johnson1, S W Moore.   

Abstract

We have previously described a catalytic monoclonal antibody, raised against acetylcholinesterase (AChE) and capable of hydrolysing acetylthiocholine. Here, we describe two more such antibodies. All three antibodies were raised against the same antigen, human erythrocyte AChE, a commercial product purified using the cholinesterase anionic site inhibitor, tetramethylammonium. IgG was purified on Protein A-Sepharose, and lack of contamination with AChE or butyrylcholinesterase (BChE) was demonstrated on sucrose density gradients and immunoassay of the fractions. The antibodies recognised AchE and were capable of hydrolysing acetylthiocholine and the larger butyrylthiocholine substrate, and were inactivated by phenylmethylsulphonyl fluoride (PMSF), indicating a serine residue in the active site. K(m), K(cat), K(cat)/K(uncat) and K(cat)/K(m) values were obtained for both substrates. The active sites of the antibodies were probed with anti-cholinesterases known to react with the active and anionic sites of acetyl- and BChE, and the peripheral anionic site of AChE. The antibodies were inactivated to varying degrees by the BChE inhibitors iso-OMPA, ethopropazine and tetracaine, indicating a less sterically constrained site than AChE and the lack of an acyl-binding pocket. They were also partially inhibited by the AChE-specific inhibitors, BW284c51 and propidium. No peripheral anionic site, as seen in AChE, was observed, shown by the almost complete lack of reaction with fasciculin. All three antibodies appear to have structures resembling the anionic sites of the cholinesterases, seen by their inhibition by quaternary and tricyclic compounds. Further work is required to determine whether the catalytic activity shown by these antibodies is germline-encoded, or is the result of complexation of the antigen with an inhibitor at a peripheral site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11275256     DOI: 10.1016/s0161-5890(00)00104-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  Molecular imprint of enzyme active site by camel nanobodies: rapid and efficient approach to produce abzymes with alliinase activity.

Authors:  Jiang-Wei Li; Lijie Xia; Youhong Su; Hongchun Liu; Xueqing Xia; Qinxia Lu; Chunjin Yang; Kalbinur Reheman
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

2.  Human α/β hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver.

Authors:  Atsushi Iwamura; Tatsuki Fukami; Ryota Higuchi; Miki Nakajima; Tsuyoshi Yokoi
Journal:  J Biol Chem       Date:  2012-01-31       Impact factor: 5.157

3.  Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice.

Authors:  Alexander V Mayorov; Neri Amara; Jason Y Chang; Jason A Moss; Mark S Hixon; Diana I Ruiz; Michael M Meijler; Eric P Zorrilla; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

4.  Functional Analysis and Molecular Docking studies of Medicinal Compounds for AChE and BChE in Alzheimer's Disease and Type 2 Diabetes Mellitus.

Authors:  Dowluru Svgk Kaladhar; Nagendra Sastry Yarla; N Anusha
Journal:  Aging Dis       Date:  2013-06-20       Impact factor: 6.745

5.  Synthesis and Biological Studies of Novel Aminophosphonates and Their Metal Carbonyl Complexes (Fe, Ru).

Authors:  Aneta Kosińska; David Virieux; Jean-Luc Pirat; Kamila Czarnecka; Małgorzata Girek; Paweł Szymański; Sławomir Wojtulewski; Saranya Vasudevan; Arkadiusz Chworos; Bogna Rudolf
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

6.  Acetylcholinesterase readthrough peptide shares sequence similarity to the 28-53 peptide sequence of the acetylcholinesterase adhesion-mediating site and competes for ligand binding in vitro.

Authors:  Glynis Johnson; Samuel W Moore
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.